ShangBay Capital

Taking the stage during Day 2 at #InnovationSanDiego for “The Dynamics of Venture Investing Today” panel session moderated by David Cassak of MedTech Strategist: Erik Engelson, Venture Partner, ShangBay Capital Thomas Shehab, MD, MMM, Managing Partner, Arboretum Ventures Amrinder Singh, Partner, Vensana Capital Erik Engelson is President & CEO of Dragon Medical, Inc, a Venture Partner with ShangBay Capital and was recently the President & CEO of Lucira Health, Inc. (now part of Pfizer). Just prior, he was CEO of Medina Medical, which he sold to Medtronic. Tom Shehab draws upon his extensive experience as a physician and healthcare executive to identify medical device and health IT companies that improve patient outcomes and decrease costs. Amrinder Singh is a Partner at Vensana Capital. Amrinder was previously a Senior Investment Director at Medtronic Ventures where he supported new investments in the medical device, diagnostics, and digital health spaces along with providing operational and board management support to portfolio companies. Remain informed on new articles, conference updates and more with our helpful #medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Inquis Medical, Inc. Medical closed a $40 million Series B financing round led by Marshall Wace. Existing investors ShangBay Capital, Yu Star, EnPointe Ventures and Pierre Lamond all participated in the oversubscribed round. ?? "This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations,” said Vahid Saadat, co-CEO and co-founder. Mojgan Saadat added: “We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.” ?? Read more: https://lnkd.in/ddazP8YQ #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

Exciting news! We are thrilled to announce that Zenflow has secured a $24M Series C financing round! This investment will be used to support our PMA submission and to prepare for commercialization of the Spring? System, a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH). The round includes new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Read our press release: https://bit.ly/3Ofn0tp #BPH #urology #menshealth

We're excited to announce late-breaking data from the RESET-RA study at the American College of Rheumatology’s #ACR24. New positive data through 24 weeks of follow-up support SetPoint System's potential as a first-of-its-kind neuroimmune modulation treatment for adults living with rheumatoid arthritis (RA). “The results from the RESET-RA study, highlighting improvements in disease severity and joint protection, underpin the continued positive clinical impact of neuroimmune modulation as a potential novel treatment for rheumatoid arthritis,” said John Tesser, MD, FACP, FACR, MACR of Arizona Arthritis & Rheumatology Associates, PC?in Phoenix, AZ, and national rheumatologist principal investigator of the study. Learn more about the late-breaking data in today's press release: https://lnkd.in/eHeAMRkk #TheSetPointAdvantage #RheumatoidArthritis #RA This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.

We are proud to announce a new collaboration with?Roche?to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology. We look forward to joining together with unwavering commitment to help more people in their fight against cancer. ?? Learn more here: https://lnkd.in/egQCFrP2 #FlareTx #oncology #transcriptionfactors #molecularbiology #biotech?#Roche

Solenic Medical Inc. Medical is proud to have been selected as a winner of the 2024 American Association of Hip and Knee Surgeons (AAHKS) Industry Innovation Award. Out of 150 exhibiting firms, 27 submissions were received, with Solenic Medical obtaining one of the two top honors. #AAHKS2024 #JointInfection #PJI #SolenicMedical

NEWS ALERT – We’re excited to announce the first trans-septal cases using the Luna TMVR system! Many thanks to our physician partners Drs. Adrian Ebner, Irakli Gogorishvili, Azeem Latib, Susheel Kodali, Edwin Ho, Gagan Singh and Vinayak Bapat for their commitment to clinical excellence in these initial cases. Read more in our release ? https://prn.to/40gfrtD #TMVR #mitralvalve #structuralheart #innovation #medtech #teamwork #clinicalexcellence #clinicaltrials

Ceribell │ AI-Powered Point-of-Care EEG seeks up to $578M valuation in upsized US IPO https://lnkd.in/gBhUm3dJ

We're pleased to announce that Setpoint has received IDE approval from the FDA to study its proprietary neuroimmune modulation platform in people living with relapsing-remitting multiple sclerosis (RRMS). “We look forward to initiating this pilot study to advance SetPoint's platform in another therapeutic area,” said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. “The results from our studies in validated preclinical models of MS suggest that the SetPoint System has the potential to address the urgent unmet medical need for novel therapies that reduce demyelination and promote remyelination – providing new hope for people living with MS.” The pilot study will be initiated in 2025 and will enroll up to 60 patients across the United States. Dive into the details here: https://lnkd.in/g6ReKNkc #TheSetPointAdvantage #MultipleSclerosis #RRMS #MS #Autoimmune This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.

Tangible Science is proud to announce our newest product: Tangible Fill Developed in collaboration with VibrantVue?, Tangible Fill is a preservative-free, additive-free saline solution formulated for rinsing GP lenses and rinsing and inserting scleral lenses. Tangible Fill is the newest addition to the Tangible Care System, working seamlessly with Tangible Hydra-PEG, Tangible Boost, and Tangible Clean to provide a complete lens care solution. Key features of Tangible Fill: - Preservative-free and additive-free formulation - Convenient 5mL unit vials (60 per box) - Completes the comprehensive Tangible Care System As eye care professionals and scleral lens wearers know, proper lens care is crucial for comfort, clarity, and eye health. Tangible Fill represents our ongoing commitment to addressing the unique needs of custom contact lens wearers and the practitioners who serve them. Tangible Fill will be available soon. To learn more and sign up for launch notifications, visit: https://lnkd.in/g4wCaCFt #scleral #sclerallens #eyecare #optometry #tangible